Engineering and improving anti-CTLA-4 checkpoint inhibitors.
Where this comes from
- Record sourced from PubMed, PMID 42258254.
- Also identified by DOI 10.1158/1078-0432.CCR-26-1059.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Next generation anti-CTLA-4 antibodies have been designed and tested to improve the efficacy and therapeutic index by leveraging enhanced Fc-mediated effector function with conditional tumour-restricted activation. The goal is to achieve robust antitumour activity without inducing systemic immune-related toxicity.